Search clinical trials for: Teclistamab (IV)

Total 3228 results

Janssen Research & Development, LLC

Recruiting

Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-1)

Hematological Malignancies

United States, Netherlands, Spain, France, Sweden
Janssen Research & Development, LLC

Not yet recruiting

A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-10)

Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC

Approved for marketing

Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients

Relapsed or Refractory Multiple Myeloma
Multiple Myeloma Research Consortium

Not yet recruiting

Horizon Adaptive Platform Trial Evaluating Therapies in RRMM

Refractory Multiple Myeloma | Relapse Multiple Myeloma
Janssen Research & Development, LLC

No longer available

Pre-approval Access Single Patient Request for Teclistamab (JNJ-64007957)

Multiple Myeloma
Janssen-Cilag Ltd.

Recruiting

A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials (REALiTEC/TAL)

Relapsed/Refractory Multiple Myeloma (RRMM)

France, Denmark, Israel, Spain, Italy, United Kingdom, Germany, Sweden
Janssen Research & Development, LLC

Active, not recruiting

A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-1)

Hematological Malignancies

Canada, United States, France, Italy, United Kingdom, Germany, Belgium, Netherlands, Spain, Sweden, China
Janssen Pharmaceutical K.K.

Active, not recruiting

A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma

Hematologic Malignancies

Japan
SCRI Development Innovations, LLC
Janssen Research & Development, LLC

Recruiting

Outpatient Administration of Teclistamab for Multiple Myeloma

Multiple Myeloma

United States
University Health Network, Toronto
Janssen Inc.

Not yet recruiting

Plan Development for Giving Teclistamab in the Outpatient Setting

Multiple Myeloma | Relapsed Cancer | Refractory Cancer
Jack Khouri

Not yet recruiting

Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM

Multiple Myeloma | Refractory Multiple Myeloma | Cytokine Release Syndrome | Immune Effector Cell Associated Neurotoxicity Syndrome

United States
Janssen Research & Development, LLC

Recruiting

A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (RedirecTT-1)

Multiple Myeloma

United States, Korea, Republic of, Canada, Israel, Spain, Japan, Australia
Carl Ola Landgren, MD, PhD
Janssen Scientific Affairs, LLC

Recruiting

Teclistamab or Talquetamab in Combination With Daratumumab for High-Risk Smoldering Myeloma (REVIVE Study) (REVIVE)

Multiple Myeloma

United States
Taipei City Hospital

Not yet recruiting

TCHCCT-Zhong-Xing-Emergency-Department Ultrasound With IV Contrast in Acute Flank Pain

Acute Flank Pain

Taiwan
Eli Lilly and Company

Completed

A Study of LY3316531 in Healthy Participants and in Participants With Psoriasis

Psoriasis

United States
Janssen Research & Development, LLC

Recruiting

A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma (TRIMM-3)

Relapsed/ Refractory Multiple Myeloma

United States, Germany, Spain, France
Healthgen Biotechnology Corp.

Completed

A Study of OsrHSA in Adult Healthy Male and Female Volunteers

Ascites Hepatic

United States
Healthgen Biotechnology Corp.

Recruiting

Study of OsrhAAT or Placebo in Healthy Volunteers

Emphysema Secondary to Congenital AATD

United States
Kyowa Kirin Co., Ltd.

Terminated

Study of KHK 4323 in Healthy Volunteers and Subjects With Atopic Dermatitis

Atopic Dermatitis

Japan
Eli Lilly and Company

Completed

A Study of LY3002813 in Participants With Alzheimer's Disease

Alzheimer Disease

United States, Japan
Asir John Samuel
Maharishi Markendeswar University (Deemed to be University)

Recruiting

Class IV Laser Therapy on Ejection Fraction, Cardio Biomarkers and Functional Outcomes

Acute Coronary Syndrome

India
GlaxoSmithKline

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Oral and Intravenous GSK1322322 in Healthy Subjects

Infections, Bacterial

United States
C. R. Bard

Completed

AccuCath Guidewire Intravenous (IV) Device Versus Conventional IV Catheter In General Nursing Use

Vascular Access Complication

United States
Wockhardt

Completed

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Intravenous WCK 771

Bioavailability

United States
Eli Lilly and Company

Completed

A Study of LY3475766 in Healthy Participants

Dyslipidemias

United States
Prometheus Biosciences, Inc., a subsidiary of Merck...
Altasciences Company Inc.

Completed

Bioavailability of SC Formulation and Japanese Ethnobridging Study for PRA023

Healthy

United States
Oculis
Neurotrials

Recruiting

OCS-05 in Patients With Acute Optic Neuritis (ACUITY)

Optic Neuritis | Optic; Neuritis, With Demyelination

France
Gmax Biopharm LLC.

Recruiting

A Study of GMA301 in Subjects With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

United States, China
Flame Biosciences

Withdrawn

Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors

Gastric Cancer | Solid Tumor | Pancreas Cancer
Qilu Pharmaceutical Co., Ltd.

Completed

Safety, Tolerability, Pharmacokinetics of Intravenous FL058 and Meropenem in Healthy Subjects(SAD/MAD)

Healthy

China
Universitaire Ziekenhuizen KU Leuven
BEDAL; Remedus

Terminated

Impact of Availability of Showerpatch for Patients With Intravenous Catheters (ISIC)

Neoplasms | Cystic Fibrosis | Pulmonary Hypertension

Belgium
Bayer

Recruiting

A Study to Learn How Safe the Study Treatment BAY2701250 is, How it Affects the Body and How it Moves Into, Through and Out of the Body in Healthy Male Participants When a Single Amount is Given as an Injection Into the Vein (Intravenous Infusion) or Under the Skin (Subcutaneous Injection)

Pulmonary Hypertension Due to Left Heart Disease

Germany
Alexion Pharmaceuticals, Inc.
Syneos Health

Completed

Study of ALXN1820 in Healthy Adult Participants

Healthy

Australia, United Kingdom
Eli Lilly and Company

Completed

A Safety Study of LY3462817 in Healthy Japanese and Non-Japanese Participants

Healthy

United States
Eli Lilly and Company

Completed

A Study of LY3361237 in Healthy Participants

Healthy

United States
Eli Lilly and Company

Terminated

A Study of LY3478006 in Healthy Participants

Healthy

United States
Eli Lilly and Company

Completed

A Study of LY3375880 in Healthy Participants

Healthy

United States
GlaxoSmithKline

Completed

Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma

Asthma

United States, Argentina, Australia, Canada, France, Germany, Japan, Russian Federation, Spain, Ukraine, Belgium, Chile, Korea, Republic of, Mexico, Italy, United Kingdom
Eli Lilly and Company

Completed

A Study of LY3200327 in Healthy Participants

Healthy

United States
William Beaumont Hospitals

Completed

Peripheral Intravenous Catheter Securement With Tissue Adhesive

Vascular Access Devices

United States
Stichting European Myeloma Network
Janssen Pharmaceutica

Recruiting

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (MajesTEC-4)

Multiple Myeloma

United Kingdom, Czechia, Australia, Austria, Belgium, Denmark, Germany, Greece, Italy, Netherlands, Norway, Serbia, Switzerland, Turkey, Brazil
International AIDS Vaccine Initiative
Beth Israel Deaconess Medical Center; Ragon Institute of MGH, MIT and Harvard; University of Texas Health, Houston AIDS Research Team (HART) and other collaborators

Completed

A Clinical Trial of PGDM1400 and PGT121 and VRC07-523LS Monoclonal Antibodies in HIV-infected and HIV-uninfected Adults

HIV Infections

United States
Edesa Biotech Inc.
JSS Medical Research Inc.

Recruiting

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients With COVID-19

COVID-19 | ARDS

United States, Canada
Astria Therapeutics, Inc.

Completed

A Study of STAR-0215 in Healthy Adult Participants

Hereditary Angioedema

United States
Eli Lilly and Company

Terminated

A Safety Study of LY3462817 and LY3509754 in Participants With Psoriasis

Psoriasis

United States, Canada
Biogen

Completed

Phase 1 Study to Evaluate the PK, Safety, Tolerability of BIIB023 in Chinese, Japanese, and Caucasian Healthy Volunteers

Healthy Volunteers

Australia, China
Alexion Pharmaceuticals

Completed

Study of Subcutaneous and Intravenous ALXN1720 With and Without rHuPH20 in Healthy Subjects

Healthy

United Kingdom
Janssen-Cilag International NV

Completed

A Safety, Tolerability, Pharmacokinetics, and Immunogenicity Study of CNTO 6785 in Healthy Volunteers

Healthy

Belgium
AstraZeneca

Completed

A Study to Evaluate the Safety and Tolerability of AZD7442 in Chinese Adults

Coronavirus Disease 2019 (COVID-19)

China
Biogen

Completed

Phase 1 Subcutaneous Single and Multiple Ascending Dose Study of BG00010 (Neublastin)

Healthy | Painful Lumbar Radiculopathy

Netherlands

Search clinical trials for: Teclistamab (IV)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Nigeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations